nrclinonc.2012.1 f1Lee J1,2, Park JY3,4, Huh KH1,2,5, Kim BS4,5,6, Kim MS1,2,5, Kim SI1,2,5, Ahn SH3,4, Kim YS1,2,5.

Abstract
BACKGROUND:

Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy. Although rituximab is increasingly used for desensitization of ABO-incompatible or positive crossmatch kidney transplantation, the risk of HBV reactivation in hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (anti-HBc)-positive kidney transplant patients receiving rituximab desensitization remains undetermined.

dt 170421 heart kidneys 800x600Pippias M, Jager KJ, Kramer A, Leivestad T, Sánchez MB, Caskey FJ, Collart F Couchoud C, Dekker FW, Finne P, Fouque D, Heaf JG,Hemmelder MH, Kramar R, De Meester J, Noordzij M, Palsson R, Pascual J, Zurriaga O, Wanner C, Stel VS

This study examines the changes of such indicators as the incidence of new cases, prevalence, patients and renal allograft survival and the causes of death of patients receiving renal replacement therapy in Europe.

kat2Permanent catheter

Insertion place

  • Neck ( internal jugular vein)
  • Femoral vein (inguinal)
  • Chest (subclavian vein)

WORKING HOURS

Monday
Tuesday
Wednesday
Thursday
Friday
Saturday
Sunday
08:00 - 18:00
08:00 - 18:00
08:00 - 18:00
08:00 - 18:00
08:00 - 18:00
08:00 - 18:00
Does not work

CONTACT

(+994 70) 396 68 44 (7/24 active)
(+994 50) 220 68 44
(+994 12) 596 68 44
(+994 12) 596 68 48
Jalil Mammadguluzadeh Street 3, AZ1009, Baku Azerbaijan